[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperactivity-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperactivity-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100647003","diagnostic-accuracy-and-safety-of-the-attention-deficithyperactivity-disorder-auxiliary-evaluation-system-ahef-in-chinese-children-aged-6-to-12-100647003",false,"NCT07683156","Diagnostic Accuracy and Safety of the Attention-Deficit\u002FHyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12","A Multicenter Prospective Clinical Study: Evaluating the Diagnostic Efficacy and Safety of the Attention-Deficit\u002FHyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12","Inclusion Criteria:\n\n* Age range: 6-12 years old, gender not restricted;\n* For children presenting for an initial ADHD diagnostic visit: presenting with common symptoms of ADHD such as inattention, hyperactivity, impulsivity, learning difficulties, behavioral problems, etc., and requiring a comprehensive assessment to confirm the diagnosis; Normal children: showing no obvious abnormal manifestations in family and school life, such as parents or teachers' initial assessment indicating basic health and normal neurodevelopmental behavioral performance, with no relevant medical history;\n* Normal intelligence (Wechsler Intelligence Scale for Children IQ ≥ 85);\n* The patient and\u002For their guardian have agreed to participate in the study and have signed the informed consent form; for participants aged 8 and above, a pediatric informed consent form must also be signed.\n\nExclusion Criteria:\n\n* Suffering from mental disorders or other neurodevelopmental disorders (such as autism spectrum disorder, schizophrenia, bipolar disorder, depressive disorder, tic disorder, reading disorder, anxiety disorders or stress-related disorders that still meet the diagnostic criteria within the last 6 months), neurological diseases such as epilepsy, and brain organic diseases, etc.;\n* Acute stage of respiratory, digestive, circulatory, urinary, immune, endocrine system diseases or acute episodes of chronic diseases (such as common acute symptoms like fever, breathing difficulties, diarrhea, etc.) and those judged by the investigator to potentially affect the research results;\n* Hearing impairment with corrected hearing not within the normal range, visual impairment with corrected vision not within the normal range, visual impairments such as color blindness, and other visual or hearing problems affecting software users;\n* Those previously diagnosed with ADHD or suspected ADHD;\n* Those who have received, are receiving, or plan to receive any psychological treatment for ADHD or non-drug treatment for the nervous system, or other cognitive, psychological-related behavioral intervention treatments in the past 6 months;\n* Those who have received neurological drug treatment (especially ADHD treatment drugs) and are still within 5 half-lives after the last medication at the time of enrollment; those who are currently receiving or plan to receive any ADHD or neurological drug treatment during the trial;\n* Those who have had gaming addiction in the past;\n* Motor conditions (e.g., hand dysfunction) reported by family members or observed by the investigator that would interfere with the trial procedures.\n* Those who have had suicidal thoughts or the investigator judges that they have suicidal impulses, non-suicidal self-harm impulses;\n* Those who are participating in other clinical trials or have not completed other trials within 1 month;\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.",true,"ALL","6 Years","12 Years",{"count":21,"type":22},570,"ESTIMATED","OBSERVATIONAL","This clinical trial aims to evaluate the diagnostic efficacy and safety of the Attention Deficit Hyperactivity Disorder Assessment System (AHEF) in children aged 6 to 12 in China, while ensuring the safety of the subjects and maintaining the scientific integrity of the clinical trial.",[26,27],"Attention-Deficit","Hyperactivity Disorder","NOT_YET_RECRUITING","2026-07-27",{"date":31,"type":32},"2026-07-29","ACTUAL",{"date":34,"type":22},"2026-07-31",{"date":36,"type":22},"2027-04-04",{"name":38,"class":39},"Chongqing Jinsaixing Medical Technology Co., Ltd","INDUSTRY",8,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":73,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100577382","the-primary-objective-of-this-study-is-to-determine-whether-positively-framed-information-pfi-on-side-effects-compared-to-negatively-framed-and-extensive-information-nfi-can-reduce-the-number-and-severity-of-reported-adverse-events-caused-by-adhd-medication-in-children-aged-7-to-17-years-100577382","NCT06797570","The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.","Nocebo Effecten Verminderen in Kinderen Met ADHD: the NOVA Study","NOVA","Inclusion Criteria:\n\n* Children aged 7 to 17 years\n* Recently diagnosed with ADHD or ADD by a psychologist\n* Desire to start ADHD\u002FADD medication expressed by both the child and the parents\n\nExclusion Criteria:\n\n* Previous use of stimulants\n* 1st or 2nd degree family member using stimulants for ADHD\u002FADD within the last two years","7 Years","17 Years",{"count":52,"type":22},130,"INTERVENTIONAL",[55],"NA","The goal of this randomized controlled care evaluation is to determine whether positively framed and concise information (PFI), compared to negatively framed and extensive information (NFI) about adverse events can reduce the number and severity of reported adverse events caused by ADHD medication in children aged 7 to 17 years. The main questions it aims to answer are:\n\n1. Does PFI reduce the percentage of children suffering from decreased appetite in the first 4 weeks after starting medication compared to NFI?\n2. Does PFI reduce the total number of adverse events compared to NFI?\n3. Does PFI lower the total score on the Pittsburgh Side Effects Rating Scale (PSRS) compared to NFI?\n4. Does PFI lead to higher parental satisfaction with the explanation of adverse events compared to NFI?\n5. Does PFI reduce the number of patients who discontinue medication due to adverse events compared to NFI?\n6. Does PFI decrease the number of patients needing melatonin for sleeping problems due to the use of methylphenidate compared to NFI?\n7. What is the relationship between baseline factors such as age, ADHD or ADD diagnosis, and gender on the number of adverse events?\n\nResearchers will compare children who receive positively framed, concise information (PFI) to those who receive negatively framed, detailed information (NFI) to determine if the framing of information affects the prevalence and severity of reported side effects, medication adherence, and parental satisfaction.\n\nParticipants in this study will:\n\n* Be randomly assigned to receive either PFI or NFI about the side effects of methylphenidate.\n* Start taking methylphenidate according to standard care protocols.\n* Complete a Pittsburgh Side Effects Rating Scale (PSRS) questionnaire 4 weeks after starting medication to report any adverse events and their severity.\n* Parents will provide feedback on satisfaction with the explanation of side effects using a short questionnaire.\n\nThis trial aims to inform best practices for communicating potential side effects to improve medication adherence and the overall treatment experience for children with ADHD and their families.",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,27,72],"Attention Deficit Disorder","Attention Deficit Disorder (ADD)","Attention Deficit Disorder with Hyperactivity","ADHD","ADD","ADHD-not Other Specified","ADHD or ADHD Traits","ADHD Predominantly Hyperactivity Type","ADHD Predominantly Inattentive Type","ADHD with Sleep Onset Insomnia","ADHD, ADD","ADHD, Predominantly Hyperactive - Impulsive","ADHD, Predominantly Inattentive Type","Hyperactivity","Inattention",[74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98],"attention deficit hyperactivity disorder","attention deficit disorder","hyperactivity","inattention","adverse drug reaction","adverse events","side effects","nocebo effect","medication side effects","patient education","communication methods","communication strategies","pediatric care","parental satisfaction","pharmacological treatment","treatment","medication adherence","medication","child health","side effect management","treatment compliance","pediatric pharmacology","positive framing","negative framing","side effect reporting","2025-01-22",{"date":101,"type":32},"2025-01-28",{"date":103,"type":22},"2025-01-25",{"date":105,"type":22},"2027-01-06",{"name":107,"class":108},"St. Antonius Hospital","OTHER"]